Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake
- 8 December 2012
- journal article
- review article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 62 (2) , 217-223
Abstract
Antibody–drug conjugates (ADCs) are developed with the goal of increasing compound therapeutic index by specific and targeted delivery of a toxic payload to the site of action while considerably reducing damage to normal tissues. Yet, off-target hepatic toxicities have been reported for several ADC. Locations of these off-target toxicities coincide with the reported locations of cell surface mannose receptor (MR). The relative proportion of agalactosylated glycans on the Fc domain (G0F vs. G1F and G2F components) in monoclonal antibody (mAb)–based biotherapeutics is closer to some disease state IgG rather than to a normal serum-derived immunoglobulin. The lack of the terminal galactose on a G0F glycan creates an opportunity for the mAb to interact with soluble and cell surface MRs. MR is a known multi-domain lectin that specifically binds and internalizes glycoproteins and immune complexes with relatively high G0F content and has been found on the surface of various cell types, including immune cells of myeloid lineage, endothelial cells, and hepatic and splenic sinusoids. In this review paper it is proposed that the mechanism of the off-target toxicities for ADC biotherapeutics is at least in part driven by the carbohydrates, specifically agalactosylated glycans, such as G0F, their interactions with MR and resulting glycan-derived cellular uptake of ADCs. Several case studies are reviewed presenting corroborating information.Keywords
This publication has 37 references indexed in Scilit:
- Increased serum clearance of oligomannose species present on a human IgG1 moleculemAbs, 2012
- New and more efficient multivalent glyco-ligands for asialoglycoprotein receptor of mammalian hepatocytesBioorganic & Medicinal Chemistry, 2011
- Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial CancersClinical Cancer Research, 2009
- Evaluation of oligosaccharide methods for carbohydrate analysis in a fully human monoclonal antibody and comparison of the results to the monosaccharide composition determination by a novel calculationJournal of Pharmaceutical and Biomedical Analysis, 2009
- Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate CancerClinical Cancer Research, 2005
- Structural Analysis of Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural IntegrityJournal of Molecular Biology, 2003
- In Vivo and in Vitro Uptake of An Anti–Cd30/Saporin Immunotoxin by Rat Liver Parenchymal and Nonparenchymal CellsHepatology, 1994
- Potential Use of Immunoconjugates for AIDS TherapyAIDS Research and Human Retroviruses, 1992
- The low uptake of an abrin A-chain immunotoxin by rat hepatic cells in vivo and in vitroCancer Letters, 1989
- Selective uptake of ricin A‐chain by hepatic non‐parenchymal cells in vitroFEBS Letters, 1986